Anti-inflammatory Properties of Antidiabetic Drugs: A "promised Land" in the COVID-19 Era?

Overview

Journal J Diabetes Complications

Specialty Endocrinology

Date 2020 Sep 9

PMID 32900588

Citations 39

Authors

Niki Katsiki

Ele Ferrannini

Affiliations

Soon will be listed here.

Abstract

Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when uncontrolled, is also recognized as an important risk factor for COVID-19 morbidity and mortality. Furthermore, certain inflammatory markers [i.e. C-reactive protein (CRP), interleukin-6 (IL-6) and ferritin] were reported as strong predictors of worse outcomes in COVID-19 positive patients. The same biomarkers have been associated with poor glycemic control. Therefore, achieving euglycemia in patients with diabetes is even more important in the era of the COVID-19 pandemic. Based on the above, it is clinically interesting to elucidate whether antidiabetic drugs may reduce inflammation, thus possibly minimizing the risk for COVID-19 development and severity. The present narrative review discusses the potential anti-inflammatory properties of certain antidiabetic drugs (i.e. metformin, pioglitazone, sitagliptin, linagliptin, vildagliptin, alogliptin, saxagliptin, liraglutide, dulaglutide, exenatide, lixisenatide, semaglutide, empagliflozin, dapagliflozin, canagliflozin), with a focus on CRP, IL-6 and ferritin.

Citing Articles

Spotlight on the Mechanism of Action of Semaglutide.

Papakonstantinou I, Tsioufis K, Katsi V Curr Issues Mol Biol. 2024; 46(12):14514-14541.

PMID: 39728000 PMC: 11674233. DOI: 10.3390/cimb46120872.

Role of C-Reactive Protein, An Inflammatory Biomarker in The Development of Atherosclerosis and Its Treatment.

Prasad K Int J Angiol. 2024; 33(4):271-281.

PMID: 39502349 PMC: 11534478. DOI: 10.1055/s-0044-1788296.

Overview of oxidative stress and inflammation in diabetes.

Weinberg Sibony R, Segev O, Dor S, Raz I J Diabetes. 2024; 16(10):e70014.

PMID: 39435991 PMC: 11494684. DOI: 10.1111/1753-0407.70014.

Exendin-4 blockade of T1R2/T1R3 activation improves Pseudomonas aeruginosa-related pneumonia in an animal model of chemically induced diabetes.

Yu S, Xu C, Tang X, Wang L, Hu L, Li L Inflamm Res. 2024; 73(7):1185-1201.

PMID: 38748233 PMC: 11214611. DOI: 10.1007/s00011-024-01891-8.

In Silico Analysis: Anti-Inflammatory and α-Glucosidase Inhibitory Activity of New α-Methylene-γ-Lactams.

Hernandez-Guadarrama A, Diaz-Roman M, Linzaga-Elizalde I, Dominguez-Mendoza B, Aguilar-Guadarrama A Molecules. 2024; 29(9).

PMID: 38731463 PMC: 11085531. DOI: 10.3390/molecules29091973.

References

Brock C, Hansen C, Karmisholt J, Moller H, Juhl A, Farmer A . Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy. Br J Clin Pharmacol. 2019; 85(11):2512-2523. PMC: 6848951. DOI: 10.1111/bcp.14063. View

Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M . Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2014; 45(3):269-78. DOI: 10.1111/hepr.12351. View

Liu X, Mei T, Chen W, Ye S . Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients. Mediators Inflamm. 2017; 2017:5032708. PMC: 5429949. DOI: 10.1155/2017/5032708. View

Aso Y, Kato K, Sakurai S, Kishi H, Shimizu M, Jojima T . Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract. 2019; 73(5):e13335. DOI: 10.1111/ijcp.13335. View

Lebovitz H . Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep. 2019; 19(12):151. PMC: 6881429. DOI: 10.1007/s11892-019-1270-y. View

Yisireyili M, Takeshita K, Hayashi M, Wu H, Uchida Y, Yamamoto K . Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model. Psychoneuroendocrinology. 2016; 73:186-195. DOI: 10.1016/j.psyneuen.2016.08.004. View

Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Sacca L . Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes. 2006; 55(4):1133-40. DOI: 10.2337/diabetes.55.04.06.db05-1076. View

Zonoozi S, Barnard M, Prescott E, Jones R, Shah F, Tzoulis P . Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series. Mediterr J Hematol Infect Dis. 2017; 9(1):e2017004. PMC: 5224814. DOI: 10.4084/MJHID.2017.004. View

De Boer S, Heerspink H, Juarez Orozco L, van Roon A, Kamphuisen P, Smit A . Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE). Diabetes Obes Metab. 2017; 19(8):1147-1154. DOI: 10.1111/dom.12925. View

10.

Chakraborty A, Chowdhury S, Bhattacharyya M . Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract. 2010; 93(1):56-62. DOI: 10.1016/j.diabres.2010.11.030. View

11.

Derosa G, Ragonesi P, Carbone A, Fogari E, Bianchi L, Bonaventura A . Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther. 2012; 14(6):475-84. DOI: 10.1089/dia.2011.0278. View

12.

Dekkers C, Petrykiv S, Laverman G, Cherney D, Gansevoort R, Heerspink H . Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018; 20(8):1988-1993. PMC: 6055757. DOI: 10.1111/dom.13301. View

13.

Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T . Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care. 2015; 39(1):139-48. DOI: 10.2337/dc15-0781. View

14.

Li X, Jia F, Zhu Z, Huang L . Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes. Artif Cells Nanomed Biotechnol. 2019; 47(1):1256-1264. DOI: 10.1080/21691401.2019.1593996. View

15.

Sawada T, Uzu K, Hashimoto N, Onishi T, Takaya T, Shimane A . Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease. J Atheroscler Thromb. 2019; 27(7):644-656. PMC: 7406405. DOI: 10.5551/jat.50807. View

16.

Simeone P, Liani R, Tripaldi R, Di Castelnuovo A, Guagnano M, Tartaro A . Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. Nutrients. 2018; 10(12). PMC: 6315606. DOI: 10.3390/nu10121872. View

17.

Katsiki N, Perakakis N, Mantzoros C . Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?. Metabolism. 2019; 98:iii-ix. DOI: 10.1016/j.metabol.2019.07.009. View

18.

Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K . Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab Syndr Obes. 2018; 11:835-843. PMC: 6267487. DOI: 10.2147/DMSO.S184767. View

19.

Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E . Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005; 54(5):1566-72. PMC: 1314967. DOI: 10.2337/diabetes.54.5.1566. View

20.

Liu Y, Jiang X, Chen X . Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease. Lipids Health Dis. 2017; 16(1):227. PMC: 5712174. DOI: 10.1186/s12944-017-0609-0. View